Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   November 2015
 
A LA UNE
11/03/2015 - Lyonbiopole and CLARA strengthen their partnership

Strong of a first successful collaboration, Lyonbiopole, the gateway for healthcare innovation in Rhône-Alpes and Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA) announced the strengthening of their partnership launched in early 2013. Their new joint plan commits both to strenghten the regional research and innovation ecosystem by 2018.


ZOOM SUR
ElsaLys Biotech

ElsaLys Biotech, Lyonbiopole's member dedicated to the development of "best-in-disease" therapeutic antibodies for oncology and ophthalmology, announces that it has completed the first stage of a € 5 million fundraising. This first stage of € 2.7 million was subscribed by Sofimac Partners, already a shareholder, and by IM Europe, a subsidiary of Institut Mérieux and Crédit Agricole Création.

Learn more



A LA UNE
11/2-4/2015 - Large Rhône-Alpes delegation to BioEurope 2015 Convention

This year again, the partnering BioEurope Fall helt in Munich was a great success with over 1800 companies and 3500 participants. The Rhône-Alpes region and Lyonbiopole were well represented with a delegation of 10 companies supported through international development plan of the cluster and funded by the Region. This edition, co-organized by our Bavarian partner, BioM cluster, was also an opportunity for the European alliance bioXclusters (Lyonbiopole, BioM, Biocat and bioPmed) to prepare the future international actions for 2016-2017.

04/13-14/2016 - BIOVISION 2016

Applications for BIOVISION Catalyzer and BIOVISION Investor Conference will open 10th December. You have until February 29th, 2016 to fill in your online application. BIOVISION Catalyzer allows start-ups and collaborative projects to get exposure and promotes meetings of B2B. BIOVISION Investor Conference provides an opportunity for companies in searching for funds.
Contact : BIOVISION Catalyzer - Hind Benjelloun, Technology and Innovation Project Manager  - hind.benjelloun@lyonbiopole.com // BIOVISION Investor Conference - Olivier Szymkowiak, Head of Financial Affairs - olivier.szymkowiak@lyonbiopole.com

Learn more



AGENDA
7th Private Inv€stments Day
December 4th,  2015 - Lyon, France
GATC Biotech event
December 4th,  2015 - Lyon, France
European Nanomedecine Meeting
December 7th to 9th, 2015 - Grenoble, France
Opera Scientific Day
December 14th 2015 - Lyon, France
Biovision 2016
April 13th and 14th 2016 - Lyon, France
AMP 2016
June 6th to 8th 2016 - Montpellier, France
 
A LA UNE
10/2015 – New H2020 Health “Personalised Medicine” 2016

The EC has publishes its new H2020 Health calls for projects for 2016. Most of the RIA – Research and Innovation actions are one-stage calls, with a deadline fixed on April 13th, 2016. Find all the details on the H2020 participant portal. Find the Health 2016-2017 Work programme here. The Health NCP Net 2.0 project together Medicen Paris Region and the Chamber of Commerce and Industry Paris Ile-de-France, member of Enterprise Europe Network, organize an international brokerage event on the H2020 Health, Demographic change and Wellbeing 2016-2017 calls, next 13 January 2016, in Paris. https://www.b2match.eu/BEHealthParis
Lyonbiopole supports its members to build up projects and find partners.
Contact : Emilie Romeo, European Project Manager – emilie.romeo@lyonbiopole.com

Learn more


10/2015 - H2020 NMBP and ICT calls 2016 open

The EC has published calls on NMBP (nanomaterials, advanced materials, biotech and production) and ICT for 2016. Many lines are dedicated to health topics. Find the information on the H2020 participant portal. Lyonbiopole supports its members to build up projects and find partners.
Contact : Emilie Romeo, European Project Manager - emilie.romeo@lyonbiopole.com

Learn more


11/2015 - H2020 SME instrument - 2016 calls

EC launches its new H2020 SME Instrument calls for 2016. The SME instrument is focused on thematic lines, like “SMEInst -05 Supporting innovative SMEs in Healthcare biotechnology sector”. Other lines are open around biotechnology and ICT in health. Applications can be filed in Phase 1 or Phase 2, by one single SME. 4 deadlines are announced in 2016 (the first time: 3/02/2016). Read the full "Innovation in SMEs 2016-2017 "program. Details on the participant portal.Lyonbiopole supports its members to build up projects and find partners.
Contact : Emilie Romeo, European Project Manager - emilie.romeo@lyonbiopole.com

10/2015 - Eurostars Programme

The new Eurostars call is open - deadline for submission announced on 18/02/2016. This program, dedicated to innovative SMEs, aimed at supporting collaborative and European, close to the market R&D projects, (minimum 2 participating European countries). The project funding rate is 30 to 40% of eligible costs. Lyonbiopole supports its members to build up projects and find partners.
Contact: Emilie Romeo, European Project Manager - emilie.romeo@lyonbiopole.com

Learn more


10/2015 - 6th IMI calls for projects open

The Joint Technology Initiative on Innovative Medicines IMI2 launches its 6th call for projects. 4 topics are open. See details here. For the first stage of academic consortia compounds, SMEs, patient organizations, regulatory agencies are invited to apply. Closing date of the first stage: 12/01/2016. Preparation webinars were organized, find all the slides here.
Contact : Emilie Romeo, European Project Manager –emilie.romeo@lyonbiopole.com
 


A LA UNE
11/2015 - A year-end firmly focused to Japan, a Lyonbiopole strategic market !

As part of its international action plan, Japan appears today as one of the strategic Asian markets targeted by the cluster. Thus for two years now, Lyonbiopole has strengthened its actions in Japan such as participation in BioJapan, organizing "SME-large groups" meetings in the Lyon area with renowned Japanese Pharmas...
Contact: Kevin Romani, SMEs Development Director - kevin.romani@lyonbiopole.com

11/23/2015 - APD closes a round of financing

APD, a start-up based in Lyon and spun off the incubator MD Start, is pleased to announce the closing of a 1.6M€ round of financing with French Venture Capital firms Sofimac Partners, Kurma Partners, Idenvest and Crédit Agricole Création. This pool of VC’s has joint former shareholders of the company comprising the management, MD Start, Simba Santé and other seasoned business angels from the Medtech industry.

Learn more


11/17-23/2015 - Poxel announced patent access agreement with ENYO Pharma and new data

POXEL SA announced a second agreement with ENYO Pharma SA, by wich Enyo accesses a key patent on the use of FXR technology to develop treatments for Hepatitis B. The company also presented positive results on two of his principals programs during The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC).

11/18/2015 - ERYTECH and Adocia receive the Deloitte In Extenso Technology Fast 50 Prize

ERYTECH Pharma has received the "Promosing Biotech Award" for the Grand Rhône-Alpes region at the 15th edition of the Deloitte Technology Fast 50 in Lyon and Adocia company has received the "Listed Company" for the Grand Rhône-Alpes region.

11/16/2015 - Novasep and CPI advance innovation

Novasep, a leading supplier of services and technologies for the life sciences industry, and the Centre for Process Innovation (CPI), a UKbased technology innovation centre, today announce they have equipped the UK National Biologics Manufacturing Centre with BioSC Lab, the latest state-of-the art technology for protein purification.

Learn more


11/13/2015 - iDD biotech present its work to the conference TherAb'15 

iDD biotech today participates in the conference TherAb'15 (Therapeutic Antibodies 2015) organized by the French CNRS network on Therapeutic Antibodies (GDR ACCITH) at the Curie Institute in Paris. Claudine Vermot-Desroches, (company’s CSO) presents an updated preclinical data on innovative Fc-engineered MAb against the attractive CD19 target for the treatment of various hematological malignancies.


11/06/2015 - Adocia announces positive Phase 1b results

Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 and type 2 diabetes. Adocia announced positive topline results from a Phase Ib randomized double-blind crossover trial of BioChaperone Combo in 28 subjects with type 1 diabetes. The study, comparing the effect on post-meal glycemic control of individualized doses of BioChaperone Combo and Humalog® Mix75/25™ (Eli Lilly) injected at the beginning of standardized meals, met its primary endpoint, demonstrating superiority of BioChaperone Combo in the reduction of post-meal blood glucose over the first two hours (Delta-AUC-BG(0-2h)) compared to Humalog® Mix75/25™.

Learn more


11/05/2015 - 7 Lyonbiopole members selected fo Big Booster Boot Camp in Boston

Cartimage Medical, Diabeloop, Kallistem, MaaT Pharma, Metabolys, Neolys Diagnostics, Novadiscovery successfully reached the second milestone of Big Booster, the first international non-profit acceleration program organized jointly by Boston (USA) and Lyon (France). After a 3-day boot camp in Lyon in October, these 7 companies were selected from among 72, to be in the top-20 European start-ups that will participate to a second boot camp in Boston in February 2016.

Learn more


11/04/2015 - BIOASTER announces its collaboration with Janssen and the Cancer Center of Lyon

 

BIOASTER, and Cancer Center of Lyon (CRCL, France) represented by its managing partners INSERM1, CNRS2, UCBL3 and CLB4, have signed a contract with Janssen-Cilag SAS, one of the Janssen Pharmaceutical Companies of Johnson & Johnson to advance the global fight against chronic hepatitis B virus (HBV). The collaboration is jointly coordinated by Janssen France and Johnson & Johnson Innovation.

Learn more


11/03/2015 - Imaxio, new vaccine candidate

The Jenner Institute at Oxford University, together with partners Imaxio and GSK, has started a phase I clinical trial of a novel vaccine candidate aimed at blocking transmission of malaria. The clinical trial is being conducted at Southampton, the lead trial site, and Oxford.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |